Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” second quarter 2025 investor ...

Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The market rallied ...

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A and why I remain bullish on BDX.

Becton, Dickinson and Company is an attractive firm that just made a good deal. Click here to find out why BDX stock is a Buy.

BECTON, DICKINSON Hedge Fund Activity We have seen 686 institutional investors add shares of BECTON, DICKINSON stock to their portfolio, and 754 decrease their positions in their most recent quarter.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD ...

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) reached a new 52-week low on Wednesday after Morgan Stanley lowered their price target on the stock from $280.00 to $196.00. Morgan ...

Fintel reports that on October 1, 2024, Citigroup upgraded their outlook for Becton, Dickinson and (NYSE:BDX) from Neutral to Buy. As of September 25, 2024, the average one-year price target for ...

Becton, Dickinson and Company (NYSE:BDX) reported revenue of $5.4 billion in fiscal Q4 2024, which showed a 6.9% growth from the same period last year.

The stock's fall snapped a four-day winning streak.